An Open-label, Multi-center, Long-term Safety Follow-up, Roll-over Study in Patients Who Have Completed a Prior Novartis-sponsored Capmatinib (INC280) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Capmatinib

Trial Profile

An Open-label, Multi-center, Long-term Safety Follow-up, Roll-over Study in Patients Who Have Completed a Prior Novartis-sponsored Capmatinib (INC280) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Capmatinib

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Capmatinib (Primary)
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 22 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 30 Jun 2017 Planned End Date changed from 27 May 2019 to 1 Jul 2019.
    • 30 Jun 2017 Planned primary completion date changed from 27 May 2019 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top